• Tamsulosin: From POUR Evidence to Assay Design

  2026-09-03

  Tamsulosin links α1A-adrenergic receptor pharmacology with measurable changes in urinary flow and smooth-muscle tone. This evidence-driven guide translates clinical findings into better receptor, tissue, and urological disease research strategies.

• Topotecan (SKF104864): Research Workflows

  2026-09-03

  Topotecan (SKF104864) provides a practical way to connect topoisomerase I inhibition with apoptosis, replication stress, and cell-cycle phenotyping. This guide emphasizes reproducible workflows for glioma, glioma stem cells, recurrent SCLC-oriented models, and pediatric solid-tumor research, with troubleshooting strategies for solubility, exposure, and assay interpretation.

• Arrb2–6-ketoLCA Axis in Hepatic IRI

  2026-09-02

  The reference study identifies hepatocyte Arrb2 as a regulator of hepatic ischemia–reperfusion injury, connecting hepatocyte metabolic output with 6-ketoLCA-driven M2 macrophage polarization. By combining transplantation-associated clinical samples, hepatocyte-focused mouse models, hypoxia–reoxygenation assays, and metabolomics, the work proposes an immunometabolic pathway that may help explain variation in liver injury and recovery.

• Angiotensin II A1042: Practical Lab Protocol

  2026-09-02

  This practical guide explains how to prepare and apply Angiotensin II (SKU A1042) for receptor-stimulation, vascular smooth muscle, oxidase, and remodeling workflows. It distinguishes product-dossier specifications from laboratory recommendations and does not present the reagent as a diagnostic, therapeutic, or paper-validated outcome without directly matched evidence.

• Naftifine HCl: From Mechanism to Translation

  2026-09-01

  A thought-leadership analysis of Naftifine HCl as an allylamine antifungal agent, connecting squalene 2,3-epoxidase inhibition with disciplined translational research, while using the WNT5a/GSK3/β-catenin study as a framework for mechanistic validation and cross-domain boundaries.

• Catalpol Workflows for Translational Research

  2026-09-01

  Catalpol supports mechanism-driven workflows spanning neuroprotection research, ischemic stroke, osteoporosis, and liver fibrosis. This guide translates its multi-target biology into practical dosing, assay-selection, and troubleshooting strategies for reproducible preclinical studies.

• P2RX1 and Mitochondrial Apoptosis in Ph+ ALL

  2026-08-31

  Li et al. identify a calcium/CaMKII-dependent mechanism by which P2RX1 overexpression suppresses PI3K/Akt signaling and promotes mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. The findings connect purinergic signaling with tyrosine kinase inhibitor sensitivity while highlighting important limits, including reliance on an engineered SUP-B15 cell model and the need for validation in resistant disease models.

• Trifluoperazine 2HCl: A Mechanism-First Assay Guide

  2026-08-31

  Trifluoperazine 2HCl is a potent dopamine D2 receptor inhibitor for mechanistic neuropharmacology, immune-cell, and cancer-model research. This guide shows how to distinguish receptor-proximal effects from ROS, autophagy, and host-defense phenotypes using evidence-centered assay design.

• CA2 Perineuronal Nets and Social Memory in Alzheimer’s

  2026-08-30

  The reference study identifies degradation of perineuronal nets in hippocampal CA2 as a causal contributor to social cognition memory loss in the 5XFAD Alzheimer’s disease model. By combining behavioral, imaging, transcriptomic, genetic, enzymatic, and pharmacological approaches, the authors show that restraining MMP-dependent proteolysis can preserve CA2 perineuronal nets and delay social memory impairment.

• Propidium Iodide: From Membrane Integrity to Translation

  2026-08-29

  Propidium iodide is more than a red fluorescent endpoint: it is a mechanistic probe of membrane failure and DNA content. This thought-leadership guide connects its assay logic with lessons from rapid microwave processing of lactoferrin, helping translational researchers improve experimental control, interpretation, and reproducibility.

• 2-Hydroxypropyl-β-cyclodextrin Protocol Guide

  2026-08-28

  2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to improve the apparent aqueous solubility of poorly soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. This guide focuses on pharmaceutical and biochemical research workflows and does not establish clinical efficacy, universal bioavailability improvement, or suitability outside documented solubilization applications.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer

  2026-08-28

  The reference study develops a nonviral strategy in which chemically modified p21 mRNA is packaged in lipid nanoparticles and administered directly into the bladder. Its data indicate that localized delivery restores tumor-suppressor activity, suppresses orthotopic tumor growth, and limits systemic exposure, while also identifying the experimental and translational constraints that remain.

• Ertapenem Sodium Salt in Carbapenem Resistance Research

  2026-08-27

  Ertapenem sodium salt offers translational researchers a mechanistically defined tool for connecting cell-wall inhibition, phenotypic susceptibility, and carbapenemase-driven transmission. By integrating product characteristics with recent CREC surveillance findings from Guangdong, this article outlines practical assay design, interpretation boundaries, and strategic opportunities for antibiotic resistance research.

• Caspases Link Autophagy to DNA Damage Adaptation

  2026-08-27

  Samarasekera and colleagues show that caspase 3 and caspase 7 can support, rather than simply terminate, stress adaptation in human breast cancer cells. Their findings connect effector caspases with cytoprotective autophagy, PARP1 modulation, H2AX phosphorylation, and selective vulnerability after BRCA1 loss.

• Niclosamide Workflows for STAT3 Cancer Research

  2026-08-26

  Niclosamide enables a practical, multi-endpoint workflow for connecting STAT3 Tyr-705 inhibition with viability loss, apoptosis, and G0/G1 arrest. Its use alongside ATRX-stratified glioma experiments and an acute myelogenous leukemia model helps distinguish pathway response from nonspecific cytotoxicity.

7827 records 1/522 page Next 12345 下5页 Last page